Abilify for bipolar disorder

The licence for Abilify (aripiprazole) has been extended to include treatment of moderate to severe manic episodes in bipolar disorder.

It has also been licensed for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

The recommended starting dose for manic episodes is 15mg once daily. The maximum daily dose should not exceed 30mg.

View Abilify drug record

Further information: Otsuka

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Insulin vial and syringe on a white background

NHS rolls out second continuous glucose monitoring device to type I diabetes patients

The Dexcom ONE device comprises a small sensor which...